Enteroporc Coli

RSS

Neonatal piglet colibacillosis vaccine (recombinant, inactivated)

Authorised
This medicine is authorised for use in the European Union.

Overview

Enteroporc Coli is a veterinary vaccine given to sows (female pigs that have already given birth to piglets) or gilts (female pigs that have not yet given birth to piglets) to protect their offspring from intestinal disease caused by Escherichia coli (E. coli). It contains parts of the E. coli bacterium called fimbrial adhesins F4ab, F4ac, F5 and F6.

This EPAR was last updated on 12/05/2021

Authorisation details

Product details
Name
Enteroporc Coli
Agency product number
EMEA/V/C/005148
Active substance
  • Inactivated fimbrial adhesins of Escherichia coli F4ab
  • Inactivated fimbrial adhesins of Escherichia coli F4ac
  • Inactivated fimbrial adhesins of Escherichia coli F5
  • Inactivated fimbrial adhesins of Escherichia coli F6
International non-proprietary name (INN) or common name
Neonatal piglet colibacillosis vaccine (recombinant, inactivated)
Species
Pigs
Anatomical therapeutic chemical veterinary (ATCvet) codes
QI09AB02
Publication details
Marketing-authorisation holder
CEVA Santé Animale
Revision
1
Date of issue of marketing authorisation valid throughout the European Union
06/01/2021
Contact address

10 avenue de La Ballastière
33500 Libourne
France

Product information

26/04/2021 Enteroporc Coli - EMEA/V/C/005148 - T/0001

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.

 

Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Immunologicals for suidae

Therapeutic indication

For the passive immunisation of progeny by active immunisation of pregnant sows and gilts to reduce clinical signs (severe diarrhoea) and mortality caused by Escherichia coli strains expressing the fimbrial adhesins F4ab, F4ac, F5 and F6.

Assessment history

How useful was this page?

Add your rating